Formulary Watch |

All News - Page 12

Health Plans Release 2024 Prescription Changes in Medicare Plans
Health Plans Release 2024 Prescription Changes in Medicare Plans
Health Plans Release 2024 Prescription Changes in Medicare Plans
October 2, 2023
Aetna, Cigna, Humana, United Healthcare — some of the largest providers of Medicare Advantage plans — have released updates to prescription drug programs.
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
Analysis: Farxiga is a High-Value Medication for Patients with Heart Failure
September 29, 2023
The recent study also found that Jardiance for patients with heart failure with preserved ejection fraction could be cost-effective if discounted by 29%.
FDA Approves Extended-Release Therapy for Major Depression
FDA Approves Extended-Release Therapy for Major Depression
FDA Approves Extended-Release Therapy for Major Depression
September 28, 2023
Exxua is approved to treat adults with major depressive disorder, but its labeling does not contain warnings about sexual function or weight gain.
ICER Adds New Measures of Value to its Assessment Framework
ICER Adds New Measures of Value to its Assessment Framework
ICER Adds New Measures of Value to its Assessment Framework
September 25, 2023
ICER adds a more formal process to evaluate the diversity of clinical trials and an assessment of a product’s impact on patient and caregiver productivity. ICER also plans to evaluate how newer methods — which would consider the change of a drug’s price over time and disease severity — can be applied to its value assessment.
Drugs to Watch: Cancer
Drugs to Watch: Cancer
Drugs to Watch: Cancer
September 22, 2023
Developing novel drugs to treat cancer remains a strong focus for drug developers. Several first-in-class therapies have become available over the last few months.
Study Finds Racial Disparities in Copay Adjustment Programs
Study Finds Racial Disparities in Copay Adjustment Programs
Study Finds Racial Disparities in Copay Adjustment Programs
September 21, 2023
Non-White patients who used copay cards were significantly more likely to encounter copay adjustment programs, such copay accumulators and maximizers, compared with their White counterparts.
Study: How PBMs Impact Drug Prices
Study: How PBMs Impact Drug Prices
Study: How PBMs Impact Drug Prices
September 21, 2023
An analysis from 3 Axis has found that PBMs control how much pharmacies are reimbursed. This can vary significantly depending on the PBM contracts with insurers, creating a system with large inconsistencies in the prices that consumers pay for both generics and branded products.
FDA Issues Complete Response for Epinephrine Nasal Spray
FDA Issues Complete Response for Epinephrine Nasal Spray
FDA Issues Complete Response for Epinephrine Nasal Spray
September 20, 2023
The FDA has requested an additional study. ARS Pharmaceuticals plans to appeal the decision.
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
FDA Advisory Committee Backs Use of Onpattro in Heart Failure Indication
September 16, 2023
Even though committee members voted in support of Onpattro for patients with cardiomyopathy related to transthyretin-mediated amyloidosis, there were questions about whether it provided a clinically meaningful benefit. The FDA set an action date of Oct. 8, 2023.
CMS Releases List of New Drugs Subject to Inflation Rebates
CMS Releases List of New Drugs Subject to Inflation Rebates
CMS Releases List of New Drugs Subject to Inflation Rebates
September 15, 2023
CMS has included an additional 34 drugs on the list on products subject to rebates if their price increases are higher than inflation.
© 2024 MJH Life Sciences

All rights reserved.